ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 214 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 0.96 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,393,821 | -95.8% | 66,882 | -95.2% | 0.00% | -94.4% |
| Q2 2023 | $33,434,344 | +290.9% | 1,396,006 | +207.1% | 0.02% | +260.0% |
| Q1 2023 | $8,554,216 | +193.3% | 454,528 | +148.1% | 0.01% | +150.0% |
| Q4 2022 | $2,916,464 | +0.5% | 183,195 | +3.3% | 0.00% | 0.0% |
| Q3 2022 | $2,902,000 | +197.0% | 177,409 | +155.7% | 0.00% | +100.0% |
| Q2 2022 | $977,000 | -48.0% | 69,370 | -10.6% | 0.00% | 0.0% |
| Q1 2022 | $1,879,000 | -5.9% | 77,571 | -9.3% | 0.00% | 0.0% |
| Q4 2021 | $1,997,000 | -28.9% | 85,558 | -49.4% | 0.00% | 0.0% |
| Q3 2021 | $2,807,000 | -14.8% | 168,967 | +25.1% | 0.00% | -50.0% |
| Q2 2021 | $3,294,000 | -88.8% | 135,043 | -88.2% | 0.00% | -87.5% |
| Q1 2021 | $29,490,000 | -47.3% | 1,143,029 | +9.2% | 0.02% | -52.9% |
| Q4 2020 | $55,952,000 | +33.2% | 1,046,611 | +2.8% | 0.03% | +17.2% |
| Q3 2020 | $41,998,000 | -20.0% | 1,018,120 | -6.0% | 0.03% | -27.5% |
| Q2 2020 | $52,481,000 | -3.2% | 1,082,755 | -15.6% | 0.04% | -16.7% |
| Q1 2020 | $54,228,000 | -2.6% | 1,283,505 | -1.4% | 0.05% | +33.3% |
| Q4 2019 | $55,703,000 | +6.6% | 1,302,139 | -10.3% | 0.04% | 0.0% |
| Q3 2019 | $52,249,000 | +30.7% | 1,451,840 | -3.0% | 0.04% | +56.5% |
| Q2 2019 | $39,987,000 | -4.7% | 1,496,092 | -4.3% | 0.02% | -8.0% |
| Q1 2019 | $41,965,000 | +29.1% | 1,563,075 | -22.3% | 0.02% | +8.7% |
| Q4 2018 | $32,509,000 | -61.2% | 2,010,567 | -50.1% | 0.02% | -4.2% |
| Q3 2018 | $83,686,000 | +26.7% | 4,031,225 | -6.8% | 0.02% | +26.3% |
| Q2 2018 | $66,066,000 | +136.7% | 4,326,638 | +248.3% | 0.02% | +46.2% |
| Q1 2018 | $27,906,000 | +4.1% | 1,242,086 | +39.5% | 0.01% | -23.5% |
| Q4 2017 | $26,806,000 | -29.6% | 890,380 | -12.0% | 0.02% | -34.6% |
| Q3 2017 | $38,096,000 | -3.9% | 1,011,415 | -28.8% | 0.03% | -7.1% |
| Q2 2017 | $39,623,000 | +5.7% | 1,420,867 | +30.3% | 0.03% | 0.0% |
| Q1 2017 | $37,478,000 | +19.1% | 1,090,227 | -0.1% | 0.03% | +12.0% |
| Q4 2016 | $31,461,000 | -18.5% | 1,091,050 | -10.2% | 0.02% | -7.4% |
| Q3 2016 | $38,626,000 | -12.1% | 1,214,367 | -10.3% | 0.03% | -12.9% |
| Q2 2016 | $43,924,000 | +40.8% | 1,353,259 | +21.3% | 0.03% | +29.2% |
| Q1 2016 | $31,190,000 | -1.9% | 1,115,618 | +25.0% | 0.02% | +9.1% |
| Q4 2015 | $31,803,000 | -11.5% | 892,170 | -17.9% | 0.02% | -21.4% |
| Q3 2015 | $35,952,000 | -21.7% | 1,087,215 | -0.9% | 0.03% | -3.4% |
| Q2 2015 | $45,928,000 | +39.0% | 1,096,724 | +8.2% | 0.03% | +38.1% |
| Q1 2015 | $33,039,000 | +189.3% | 1,013,871 | +181.8% | 0.02% | +200.0% |
| Q4 2014 | $11,422,000 | +29.3% | 359,803 | +0.8% | 0.01% | +40.0% |
| Q3 2014 | $8,833,000 | +22.7% | 356,851 | +11.9% | 0.01% | 0.0% |
| Q2 2014 | $7,200,000 | +35.1% | 318,841 | +45.6% | 0.01% | +25.0% |
| Q1 2014 | $5,329,000 | +49.9% | 219,039 | +53.9% | 0.00% | +33.3% |
| Q4 2013 | $3,555,000 | -40.1% | 142,303 | -34.2% | 0.00% | -25.0% |
| Q3 2013 | $5,938,000 | – | 216,215 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |